Baloxavir Marboxil

Abstract

Each month, subscribers to The Formulary Monograph Service receive 5 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are available online to subscribers. Monographs can be customized to meet the needs of a facility. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service, contact Wolters Kluwer customer service at 866-397-3433.

Keywords

Formulary Management/P & T Infectious Diseases Drug Information

Get full access to this article

View all access options for this article.

References

Farley

NDA approval letter: Xofluza (baloxavir marboxil) (NDA 210854). Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2018/210854Orig1s000ltr_ReplacementLtr.pdf. Published October 24, 2018. Accessed November 5, 2018.

Xofluza (baloxavir marboxil) [prescribing information]. South San Francisco, CA: Genentech USA, Inc; October 2018.

Genentech. FDA grants priority review to Genentech’s baloxavir marboxil for the treatment of influenza [news release]. https://www.gene.com/media/press-releases/14732/2018-06-25/fda-grants-priority-review-to-genentechs. Published June 25, 2018. Accessed October 7, 2018.

Noshi

Kitano

Taniguchi

et al . In vitro characterization of baloxavir acid, a first-in-class cap-dependent endonuclease inhibitor of the influenza virus polymerase PA subunit. Antiviral Res. 2018;160:109-117. doi:10.1016/j.antiviral.2018.10.008

Omoto

Speranzini

Hashimoto

et al . Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil. Sci Rep. 2018;8(1):9633. doi:10.1038/s41598-018-27890-4

Shionogi. Shionogi announces positive top-line results for baloxavir marboxil phase III study (CAPSTONE-2) in individuals at high risk for influenza-related complications [news release]. http://www.shionogi.co.jp/en/company/news/2018/pmrltj0000003w9m-att/e_180717.pdf. Published July 17, 2018. Accessed July 19, 2018.

Watanabe

Hirotsu

Ishida

et al . Pharmacokinetic/pharmacodynamic analysis of S-033188, an influenza cap-dependent endonuclease inhibitor, from a phase 2, randomized, double-blind, placebo-controlled study in otherwise healthy adults with seasonal influenza [abstract]. 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID); April 22-25, 2017; Vienna, Austria.

Koshimichi

Ishibashi

Kawaguchi

Sato

Kawasaki

Wajima

Safety, tolerability, and pharmacokinetics of the novel anti-influenza agent baloxavir marboxil in healthy adults: phase I study findings. Clin Drug Investig. 2018;38(12):1189-1196. doi:10.1007/s40261-018-0710-9

Centers for Disease Control and Prevention. Influenza antiviral medications: summary for clinicians. https://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm. Updated February 23, 2018. Accessed July 20, 2018.

10.

Hayden

Sugaya

Hirotsu

et al . Baloxavir marboxil for uncomplicated influenza in adults and adolescents. N Engl J Med. 2018;379(10):913-923.

11.

Portsmouth

Kawaguchi

Arai

Tsuchiya

Uehara

Cap-dependent endonuclease inhibitor S-033188 for the treatment of influenza: results from a phase 3, randomized, double-blind, placebo- and active-controlled study in otherwise healthy adolescents and adults with seasonal influenza [abstract LB-2]. Open Forum Infect Dis. 2017;4(suppl 1):S734.

12.

Shionogi. A study of S-033188 (baloxavir marboxil) compared with placebo or oseltamivir in otherwise healthy patients with influenza (CAPSTONE 1). https://www.clinicaltrials.gov/ct2/show/record/NCT02954354. Updated July 6, 2018. Accessed July 20, 2018. NLM Identifier: NCT02954354.

13.

Shionogi. Shionogi presents positive results for baloxavir marboxil phase III study (CAPSTONE-2) in individuals at high risk for influenza-related complications at IDWeek 2018 [news release]. http://www.shionogi.co.jp/en/company/news/2018/pmrltj0000003xis-att/e_181004.pdf. Published October 4, 2018. Accessed October 8, 2018.

14.

Shionogi. Study of S-033188 (baloxavir marboxil) compared with placebo or oseltamivir in patients with influenza at high risk of influenza complications (CAPSTONE 2). https://www.clinicaltrials.gov/ct2/show/NCT02949011. Updated July 6, 2018. Accessed May 3, 2018. NLM Identifier: NCT02949011.

15.

Ison

Portsmouth

Yoshida

et al . Phase 3 trial of baloxavir marboxil in high-risk influenza patients (CAPSTONE-2 study) [abstract]. Open Forum Infect Dis. 2018;5(suppl 1):S764.

16.

FluMist Quadrivalent (influenza vaccine live intranasal) [prescribing information]. Gaithersburg MD: MedImmuneLLC; August 2018.

17.

Fukao

Ando

Noshi

et al . Delayed dosing of S-033188, a novel inhibitor of influenza virus cap-dependent endonuclease, exhibited significant reduction of viral titer and mortality in mice infected with influenza A virus [abstract 1514]. Open Forum Infect Dis. 2017;4(suppl 1):S473.

18.

Kawaguchi

Koshimichi

Ishibashi

Wajima

Evaluation of drug-drug interaction potential between baloxavir marboxil and oseltamivir in healthy subjects. Clin Drug Investig. 2018;38(11):1053-1060.